|
All Business Categories
|
VIRxSYS Corporation
Maryland, USA >VIRxSYS corporation is a private biotech company whose mission is to develop gene therapies using its proprietary lentiviral vector delivery system. The company is in Phase II cli... Nuvelo , Inc. California, USA Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nu... Diosynth Illinois, USA Diosynth develops new method for manufacturing synthetic peptides Fujisawa Healthcare , Inc. Illinois, USA Fujisawa Healthcare, Inc., headquartered in Deerfield, IL, develops, manufactures, and markets proprietary pharmaceutical products in the United States and abroad. Fujisawa Healthc... Trigen Ltd London, United Kingdom Trigen previously announced the successful completion of a Phase I dose escalation study on TGN 167 using a classical rapid release tablet formulation. Trigen is developing TGN 167... Massachusetts, USA Microbia is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Microbia is committed to delivering new medicines into important markets... Neurologix , Inc. New Jersey, USA Neurologix, Inc. is a development-stage company engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system utilizing ge... Biota Holdings Limited Victoria, AUSTRALIA Biota is a world-leading antiviral drug discovery company with its headquarters in Melbourne, Australia. Biota's first breakthrough was the discovery of zanamivir, the first neuram... Panacea Pharmaceuticals , Inc. Maryland, USA Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with subst... SGX Pharmaceuticals , Inc. California, USA SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The company's lead product candidate, ...
First
Prev
[17]
[33]
[49]
[66]
[67]
[68]
[69]
[70]
[71]
[72]
[73]
[74]
[75]
76
[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]
[127]
[170]
[213]
Next
Last
|
